Nev Black Posted January 11, 2019 Share Posted January 11, 2019 Professor Ho, Dr Rhee, Dr Oleinikova and Dr Navaratnam ran a Novel Liver Targeted Therapy for Sarcopenia in Androgen deprived men with Prostate Cancer commencing in the latter part of 2016. Sarcopenia is a component of cachexia, weakness and wasting of the body due to severe chronic illness. This leads to loss of muscle strength and fatigue. The trial papers said ‘The annualised loss of lean body mass is about 10 times that occurring with ageing. Thus sarcopenia prevention during ADT remains a major treatment frontier for prostate cancer.’ David Abrahams and I elected to join the trial as we had both been on ADT for a number of years. Personally, I have been on Eligard continually since April 2011. I have the Ozcare nurse come to our home every twenty eight days to administer the two part injection. The Blind Trial involved taking, by mouth, a testosterone tablet or a placebo tablet for six months. Blood test were taken at commencement of the trial, three month and at the end of the trial. These blood test were made available to us. We also had a DEXA Scan before and after the trial. This scan is the same as the one used for measuring bone density. Without going into a whole lot of complicated detail, a small dose of Testosterone taken by mouth is absorbed by the stomach and then the liver. An oral dose of 40 mg/day may equal as much as 250 mg by injection. As the liver is immediately breaking down the oral dose it does not increase the levels in the testosterone in the overall circulation making it safe for men on ADT. A recent letter from the PA said the study has now been unblinded. David and I were in the placebo group. Data analysis has commenced and we will be advised of the findings in due course. Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.